Bausch + Lomb shares are trading higher after the company announced it entered into a definitive agreement with Novartis to acquire XIIDRA.
Portfolio Pulse from Benzinga Newsdesk
Bausch + Lomb has entered into a definitive agreement to acquire XIIDRA from Novartis. This has led to an increase in Bausch + Lomb's share prices.
June 30, 2023 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Novartis has entered into a definitive agreement to sell XIIDRA to Bausch + Lomb.
While Novartis is selling XIIDRA to Bausch + Lomb, the impact on its share prices is uncertain without further information on the financial details of the deal.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Bausch + Lomb's acquisition of XIIDRA from Novartis has led to a rise in its share prices.
The acquisition of XIIDRA, a potentially profitable asset, by Bausch + Lomb has been positively received by the market, leading to a rise in its share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100